Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Honest Company Inc (HNST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Honest Company Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Honest Company Inc trades at $3.9 (market cap $433.71M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 10.4× Honest Company Inc's market cap. Which is the better fit depends on your goals.
| ACAD | HNST | |
|---|---|---|
Market Cap | $4.49B | $433.71M |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $4.95 |
52-Week Low | $20.06 | $2.10 |
Enterprise Value | $3.69B | $355.11M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
HNST trades at $3.94, up 1.03% with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting expectations, but maintains negative net income margins. Revenue declined to $371.32M in 2025 from $378M in 2024, though gross margins improved to 33.89%. Operating cash flow strengthened to $15.12M, supporting liquidity. Analyst sentiment is mixed with 30% buy ratings amid ongoing profitability challenges.
The outlook remains cautious due to persistent net losses and revenue volatility. Investment appeal hinges on margin expansion and sustained cash flow generation. Key risks include competitive pressures in personal care and execution on growth initiatives. The stock's elevated P/E of 48.83 suggests high expectations for future earnings recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →
